Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core

加速药物合作——自身免疫和免疫疾病组织研究核心

• 批准号: 10687729
• 负责人: Joel Marvin Guthridge
• 金额: $ 14.13万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-23 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10687729
• 关键词: Attention; Autoimmune; Autoimmune Diseases; Awareness; Biological Markers; Biopsy; Biotechnology; Caring; Cells; Certification; Characteristics; Cladribine; Clinical; Collection; Country; Data; Data Set; Database Management Systems; Dedications; Disease; Emerging Technologies; Ensure; Equipment and supply inventories; Foundations; Freezing; Government; Histology; Image; Immune; Immune System Diseases; Industry Standard; Information Systems; Infrastructure; Institution; Institutional Review Boards; International; Investments; Knowledge; Leadership; Location; Logistics; Lupus; Lupus Erythematosus; Manuals; Measurement; Mediating; Medical Research; Medicine; Methods; Mission; Modality; Molecular; Molecular Genetics; Molecular Profiling; Monitor; Multiomic Data; Oklahoma; Pathology; Patients; Phenotype; Play; Positioning Attribute; Procedures; Process; Protocols documentation; Psoriasis; Quality Control; Recording of previous events; Research; Rheumatoid Arthritis; Sampling; Science; Secure; Services; Shipping; Ships; Site; Sjogren' s Syndrome; Solid; Staff Development; Standardization; Support System; System; Systemic Lupus Erythematosus; Systems Integration; Technology; Testing; Tissue Banks; Tissue Sample; Tissue imaging; Tissues; Training; Universities; Work; adjudication; biobank; clinical application; clinically actionable; cohort; cost effective; design; digital imaging; digital pathology; distributed data; experience; high dimensionality; innovation; interest; migration; molecular phenotype; multiple omics; pathology imaging; phenotypic biomarker; programs; repository; single cell analysis; social; success; transcriptomics

Project Summary The successful Accelerating Medicines Partnership in RA/Lupus (AMP1) program focused on deconstructing disease tissues through single-cell transcriptomic technologies. AMP in Autoimmune and Immune-Mediated Diseases (AMP AIM) is poised to expand the understanding of the cellular components and interactions at play in four autoimmune disease target tissues with new spatially-oriented modalities of single-cell analyses. As in the AMP1, the AMP AIM will require high-quality samples for interrogation, standardized methods to assess sample quality and common molecular/phenotypic biomarker testing across all subjects for a clinically and molecularly well-phenotyped cohort to apply new cutting-edge technologies to re-construct disease. The OMRF tissue research core (TRC) is uniquely positioned to successfully deploy a centralized TRC across all Disease Teams for Lupus (SLE), RA, Sjogren’s Disease (SjD), and Psoriatic Spectrum Diseases (PSD). With a robust, existing infrastructure, capabilities, and leadership, the OMRF TRC will provide the Network with: 1) standardized protocols and manuals to be used across all parts of the Network, 2) centralized logistics for collection, transport, storage and dissemination, 3) centralized, trans-disease QC and initial testing of all samples in a continuous manner as samples are collected for early quality management and identification of samples of high importance, 4) tissue imaging (basic histology & initial high-dimensional) utilizing sample sparing workflows that provide scoring and QC of tissue, plus initial multi-omic, spatially-informed data sets, and 5) industry standard repository and image database systems. The OMRF TRC is centrally located, making it an ideal location for logistics management and, since it was the repository for AMP1 carries Network knowledge along with the extensive experience as repository for multiple other national consortiums, provides for continuity during transition to AMP AIM. The OMRF TRC already has infrastructure in place and the reputation that follows from strong leadership to continue to act as an ideal honest broker for the Network. The OMRF TRC has state-of-the-art facilities that are integrated with advanced technologies within its associated cores to receive, store, collect meaningful QC and initial data sets, and disseminate selected samples to technology and analytic cores (TAC) poised to provide data from emerging technologies to build upon the deep clinical and initial characterization data, to make extremely high- dimensional, robust datasets. Considering the longstanding history of the OMRF TRC in biobanking samples for autoimmune disease studies, the OMRF TRC is poised to a produce a solid foundation of banked samples, organized logistics, and initial multi-omic datasets that will setup the Network for success in reconstructing our mechanistic understanding and clinical application of these new data to better treat these autoimmune diseases.

项目摘要 RA/LUPUS（AMP1）计划的成功加速药物合作伙伴关系侧重于解构 通过单细胞转录组技术进行疾病组织。自身免疫和免疫介导的AMP 疾病（AMP AIM）被中毒以扩大对细胞成分和相互作用的理解 在四个自身免疫性疾病中，单细胞分析的新型定向方式。如 AMP1，AMP AIM将需要高质量的样本进行询问，标准化方法来评估 样品质量和常见的分子/表型生物标志物测试临床和 分子良好的类型队列将新的尖端技术应用于重建疾病。 OMRF组织研究核心（TRC）的独特位置可以成功部署集中式TRC 在所有狼疮（SLE），RA，Sjogren病（SJD）和银屑病谱系疾病的疾病团队中 （PSD）。 OMRF TRC具有强大的现有基础设施，能力和领导才能，将提供 网络与以下网络：1）在网络的所有部分中使用的标准化协议和手册，2）集中式 收集，运输，存储和传播的物流，3）集中式，跨性别QC和初始测试 在收集样本以进行早期质量管理和识别时，所有样品的连续样品中 高度重要性的样品，4）使用样品的组织成像（基本组织学和初始高维） 提供组织评分和QC的保证工作流程，以及初始多摩变，空间信息的数据集， 5）行业标准存储库和图像数据库系统。 OMRF TRC位于中央位置，使其成为物流管理的理想场所，因为它是 AMP1的存储库带有网络知识以及广泛的经验作为存储库 在过渡到AMP AIM期间，多个其他国家联盟提供了连续性。 OMRF TRC 已经设有基础设施以及强大领导才能继续充当的审查 一个理想的诚实经纪人。 OMRF TRC具有与 其相关核心内的高级技术接收，存储，收集有意义的QC和初始数据集， 并将选定的样品传播到技术和分析核心（TAC）中毒，以提供来自 新兴技术以深层临床和初始表征数据为基础，以使极高的高 尺寸，健壮的数据集。 考虑到自身免疫性疾病的生物库中OMRF TRC的长期历史 研究，OMRF TRC被毒成为靠近的样本，有组织的物流和 最初的多摩变数据集将设置网络以成功重建我们的机械 了解和临床应用这些新数据以更好地治疗这些自身免疫性疾病。